Arhalofenate - CymaBay Therapeutics
Alternative Names: JNJ 39659100; K-118; MBX-102; MetaglidasenLatest Information Update: 26 Mar 2024
At a glance
- Originator Metabolex
- Developer CymaBay Therapeutics
- Class Amides; Anti-inflammatories; Antigouts; Antihyperglycaemics; Insulin sensitisers; Small molecules; Uricosurics
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gout; Type 2 diabetes mellitus
Most Recent Events
- 22 Mar 2024 CymaBay Therapeutics has been acquired by Gilead Sciences
- 12 Jul 2019 Discontinued - Phase-II for Gout (Combination therapy) in Canada, Georgia, USA (PO) (Cymabay Therapeutics pipeline, July 2019)
- 12 Jul 2019 Discontinued - Phase-II for Gout (Monotherapy) in Canada, Georgia, USA (PO) (Cymabay Therapeutics pipeline, July 2019)